Capital Fund Management S.A. bought a new stake in Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 19,700 shares of the biopharmaceutical company’s stock, valued at approximately $283,000.
Other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $2,194,000. Falcon Point Capital LLC raised its position in Lexicon Pharmaceuticals by 3.5% in the second quarter. Falcon Point Capital LLC now owns 287,809 shares of the biopharmaceutical company’s stock valued at $4,130,000 after buying an additional 9,816 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new position in Lexicon Pharmaceuticals during the second quarter valued at $257,000. Acadian Asset Management LLC bought a new position in Lexicon Pharmaceuticals during the second quarter valued at $863,000. Finally, Eagle Asset Management Inc. raised its position in Lexicon Pharmaceuticals by 13.3% in the second quarter. Eagle Asset Management Inc. now owns 1,678,732 shares of the biopharmaceutical company’s stock valued at $24,089,000 after buying an additional 196,759 shares during the last quarter.
Shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded down 4.19% during midday trading on Friday, hitting $16.70. 785,109 shares of the stock were exchanged. The firm’s 50 day moving average price is $17.35 and its 200-day moving average price is $15.00. The stock’s market cap is $1.73 billion. Lexicon Pharmaceuticals Inc. has a 52-week low of $7.65 and a 52-week high of $19.62.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.04. The firm earned $20.10 million during the quarter, compared to analyst estimates of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. Lexicon Pharmaceuticals’s quarterly revenue was up 5186.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.27) EPS. On average, equities research analysts expect that Lexicon Pharmaceuticals Inc. will post ($1.54) earnings per share for the current fiscal year.
Several equities analysts recently weighed in on LXRX shares. Stifel Nicolaus increased their price target on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Wedbush restated a “buy” rating and set a $33.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 11th. Citigroup Inc. increased their price target on shares of Lexicon Pharmaceuticals from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, HC Wainwright started coverage on shares of Lexicon Pharmaceuticals in a research report on Friday, October 7th. They set a “buy” rating and a $26.00 price target for the company. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.86.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.